DEC 14   

Licence Agreement with SK-Pharma for the Commercial Launch of Fortacin in Israeli and Balkan Regions and Operations Update


DEC 01   

Monthly Return of Equity Issuer on Movements in Securities


NOV 01   

Monthly Return of Equity Issuer on Movements in Securities


OCT 15   

Monthly Return of Equity Issuer on Movements in Securities (Revised)


OCT 04   

Monthly Return of Equity Issuer on Movements in Securities


SEP 01   

Monthly Return of Equity Issuer on Movements in Securities


AUG 27   

List of Directors and Their Roles and Functions


AUG 27   

Unaudited Interim Results for the Six Months Ended 30 June 2021


AUG 17   

Date of Board Meeting


AUG 05   

Discloseable Transaction - Disposal of Listed Securities


AUG 04   

Monthly Return of Equity Issuer on Movements in Securities


AUG 03   

Positive Profit Alert


JUL 28   

Extremely Encouraging US Market Research Analysis for Fortacin


JUL 26   

Supplemental Announcement – Possible Issuance of Shares under General Mandate


JUL 15   

Strongly Positive Results of Fortacin US Phase II PRO Validation Study


JUL 14   

Launch of MindAge Psychological Aging Clock, Key Appointments to Scientific Advisory Board of Deep Longevity Limited and Possible Issuance of Shares under General Mandate


JUL 02   

Monthly Return of Equity Issuer on Movements in Securities


JUN 23   

Change of Company Name, Stock Short Name, Company Logo and Company Website


JUN 15   

Supplemental Announcement Relating to Offer to Grant Share Option


JUN 08   

Offer to Grant Share Option


JUN 02   

Monthly Return of Equity Issuer on Movements in Securities


MAY 31   

CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVES


MAY 28   

Poll Results at Annual General Meeting


MAY 11   

Operational update


MAY 04   

Monthly Return of Equity Issuer on Movements in Securities


APR 26   

Notice of Annual General Meeting


Apr 08   

Monthly Return of Equity Issuer on Movements in Securities


APR 01   

Operations update: Chinese approval and commercialisation progress – Fortacin™


MAR 30   

Audited final results for the year ended 31 December 2020 and proposed change of company name


MAR 18   

Notice of Board Meeting for audited final results for the year ended 31 December 2020


MAR 02   

Profit warning and operational update


Mar 02   

Monthly Return of Equity Issuer on Movements in Securities


FEB 09   

Operations update: Chinese approval and commercialisation progress – Fortacin™


FEB 02    

Monthly Return of Equity Issuer on Movements in Securities


JAN 18   

Operations update on Fortacin™


JAN 13   

Discloseable Transaction: Disposal of shares in Tigers Realm Coal Limited


JAN 11   

Operations update on Fortacin™


Jan 06   

Monthly Return of Equity Issuer on Movements in Securities


JAN 04   

Operations update on Fortacin™